- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Amlodipine and Cardiovascular outcomes in Hypertensive patients: What Meta-analysis says
![Amlodipine and Cardiovascular outcomes in Hypertensive patients: What Meta-analysis says Amlodipine and Cardiovascular outcomes in Hypertensive patients: What Meta-analysis says](https://medicaldialogues.in/h-upload/2020/01/16/750x450_123030-bp.jpg)
A major risk factor for cardiovascular disease is hypertension. A multitude of drugs, including calcium channel blockers (CCBs), β-blockers, angiotensin receptor blockers (ARBs), Angiotensin-converting enzyme inhibitors (ACEIs) as well as Diuretics have been used as monotherapy or in combination to treat hypertension (1). Initially used for coronary heart disease (CHD), CCBs over the past few years has gained wide recognition for their efficacy in the treatment of hypertension (HTN). CCBs are also being used for angina, peripheral vascular disease, and certain arrhythmic conditions apart from Hypertension (2).
Amlodipine can be safely used in high-risk cardiac patients and is associated with benefits for all major cardiovascular endpoints and total mortality.
Amlodipine-based regimens reduced the risk of total cardiovascular events and mortality compared with non-calcium channel blocker antihypertensive therapies.
They further added that Amlodipine had a protective effect against myocardial infarction and stroke.
Amlodipine can be safely used in high-risk cardiac patients and is associated with benefits for all major cardiovascular endpoints as well as total mortality.
- Minimizing the confounding effect of variability of treatment due to the substantial difference between DHPs and non-DHP CCBs.
- The study was limited to data from actively controlled trials to minimize the effect of blood pressure reductions observed in placebo-controlled trials.
- Only trials that evaluated long term outcomes and having clearly defined primary and secondary endpoints were enrolled.
Dr Prem Aggarwal, (MD Medicine, DNB Cardiology) is a Cardiologist by profession and also the Co-founder of Medical Dialogues. He is the Chairman of Sanjeevan Hospital in Central Delhi and also serving as the member of Delhi Medical Council
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751